topotecan / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

47 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
topotecan / Generic mfg.
2008-005176-28: A PROSPECTIVE PHASE II MULTICENTRIC STUDY OF WEEKLY TOPOTECAN AND CISPLATIN (TOPOCIS) AS NEOADJUVANT TREATMENT IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CERVICAL CANCER

Ongoing
2
79
Europe
Powder for infusion*, Solution for infusion, HYCAMTIN, CISPLATINO TEVA*EV 10MG 20ML
ISTITUTO NAZIONALE PER LA CURA TUMORI
Locally advanced cervical carcinoma
 
 
CCLG-NB-2006-05, NCT00392340 / 2005-000915-80: Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma

Unknown status
2
63
Europe
filgrastim, doxorubicin hydrochloride, topotecan hydrochloride, vincristine sulfate
Children's Cancer and Leukaemia Group, University of Birmingham,
Neuroblastoma
01/10
 
NCT01387386: Randomized Phase II Study of Single Agent OSI-906 Versus Topotecan for Relapsed Small Cell Lung Cancer (SCLC)

Active, not recruiting
2
95
US
Topotecan, Hycamtin®, OSI-906, TKI, Tyrosine Kinase Inhibitor, Insulin Growth Factor-1 Receptor, IGF-1R, NSC-751082
H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI)
Lung Cancer
07/14
07/14
2006-004084-66: A phase II study on the efficacy and safety of topotecan in the treatment of patients with brain metastases

Ongoing
2
19
Europe
TOPOTECAN, HYCAMTIN*INFUS IV 5F 5ML 4MG, HYCAMTIN*INFUS IV 5F 5ML 4MG
OSPEDALE ONCOLOGICO DI BARI
Brain metastases
 
 
2005-002495-15: \"Estudio exploratorio fase II para evaluar la eficacia y seguridad de topotecan semanal en el tratamiento de cáncer de cérvix persistente o recidivante tras fracaso de tratamiento de primera línea con derivados del platino\".

Ongoing
2
52
Europe
HYCAMTIN 4 mg polvo concentrado para solución para perfusión, HYCAMTIN 4 mg polvo concentrado para solución para perfusión, HYCAMTIN 4 mg polvo concentrado para solución para perfusión
Grupo Español de Investigación en Cáncer de Ovario (GEICO)
Carcinoma de cérvix escamoso o no escamoso persistente o recidivante.
 
 
2005-002499-14: \"Protocolo fase II de tratamiento con Topotecan e irradiación holocraneal en metástasis cerebrales\".

Ongoing
2
48
Europe
HYCAMTIN, HYCAMTIN 4 polvo concentrado para solución para perfusión, HYCAMTIN 4 polvo concentrado para solución para perfusión
Grupo Español de Neurooncología Médica (GENOM)
Pacientes adultos con metástasis cerebrales.
 
 
2009-012644-16: PHASE 2 SINGLE- ARM STUDIES OF TEMOZOLOMIDE IN COMBINATION WITH TOPOTECANIN REFRACTORY AND RELAPSED NEUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURS

Ongoing
2
20
Europe
TEMODAL, HYCAMTIN, TEMODAL, HYCAMTIN
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
NEUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURS
 
 
2012-001440-22: A PHASE II TRIAL ON NON-SMALL-CELL LUNG CANCER STEM CELLS SENSITIVITY ASSAY (LUCAS) Studio di fase II che valuta la sensibilita\' ai farmaci in pazienti affetti da tumore polmonare non-a-piccole-cellule

Ongoing
2
54
Europe
CARBOPLATINO TEVA IV 10F 10MG, GEMZAR*INF 1FL 200MG, TAXOLO, ALIMTA*1FL POLV 500 MG, TOPOTECAN TEVA*EV 1FL 4MG/4ML, OXALIPLATINO RAT*EV 1FL 100MG, ETOPOSIDE EBEWE*EV 5 ML 20MG/ML, TARCEVA*30CPR RIV 150MG, CARBOPLATINO TEVA IV 10F 10MG, GEMZAR*INF 1FL 200MG, TAXOLO, ALIMTA*1FL POLV 500 MG, TOPOTECAN TEVA*EV 1FL 4MG/4ML, OXALIPLATINO RAT*EV 1FL 100MG, ETOPOSIDE EBEWE*EV 5 ML 20MG/ML, TARCEVA*30CPR RIV 150MG
Histologically/cytologically confirmed diagnosis of metastatic NSCLC. Possibility to obtain tumor tissue form primary tumor or from an accessible metastatic site, or possibility to collect any neoplastic effusion. Performance status of 0-1 according to ECOG score. Diagnosi di NSCLC metastatico confermata istologicamente/citologicamente. Possibilità di ottenere tessuto tumorale dal tumore primitivo o da un sito metastatico accessibile, o possibilità di raccogliere versamenti neoplastici. Performance status di 0-1 secondo I criteri ECOG.
 
 
ChiCTR-TRC-13003443: An open-label, single-center, prospective investigation on the efficacy and safety of the chemotherapeutic regimens containing intermediate dosages of cytarabine as consolidation therapy for acute myelogenous leukemia patients

Completed
2
180
 
1. Consolidation therapy with DA regimen: Intravenous injection daunorubicin (45mg/m2/day) from day 1 through day 3, combined with 1.5g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5. ;2. Consolidation therapy with HA regimen: Intravenous injection Homoharringtonine (4mg/m2/day) from day 1 through day 5, combined with 1.5g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5 ;3. Consolidation therapy with EA regimen: Intravenous injection Etoposide (100mg/m2/day) from day 1 through day 5, combined with 1.5g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;4. Consolidation therapy with MA regimen: Intravenous injection Mitoxanetrone (7mg/m2/day) from day 1 through day 3, combined with 1.5g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;5. Consolidation therapy with TA regimen: Intravenous injection Topotecan (1.25mg/m2/day) from day 1 through day 5, combined with 1.5g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5. ;6. Consolidation therapy with AA regimen: Intravenous injection Aclarubicin (20mg/m2/day) from day 1 through day 5, combined with 1.5g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;7. Prophylaxis of central nervous system leukemia (CNS-L): intrathecal injection with 5mg dexamethasone plus 15mg MTX for 6 times totally after achievement of CR. ;1. Consolidation therapy with DA regimen: Intravenous injection daunorubicin (45mg/m2/day) from day 1 through day 3, combined with 2.0g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;2. Consolidation therapy with HA regimen: Intravenous injection Homoharringtonine (4mg/m2/day) from day 1 through day 5, combined with 2.0g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5. ;3. Consolidation therapy with EA regimen: Intravenous injection Etoposide (100mg/m2/day) from day 1 through day 5, combined with 2.0g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;4. Consolidation therapy with MA regimen: Intravenous injection Mitoxanetrone (7mg/m2/day) from day 1 through day 3, combined with 2.0g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;5. Consolidation therapy with TA regimen: Intravenous injection Topotecan (1.25mg/m2/day) from day 1 through day 5, combined with 2.0g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;6. Consolidation therapy with AA regimen: Intravenous injection Aclarubicin (20mg/m2/day) from day 1 through day 5, combined with 2.0g/m2 of cytarabine twice a day with over 3-hours infusion at day 1, 3 and 5; ;7. Prophylaxis of central nervous system leukemia (CNS-L): intrathecal injection with 5mg dexamethasone plus 15mg MTX for 6 times totally after achievement of CR.
Department of Hematology, the Second Affiliated Hospital of Dalian Medical University.; Level of the institution：, LiaoNing Project for Medicine Peak Construction (No.201112;2011-2013). 200,000 Yuan.
acute myelogenous leukemia
 
 
NCT00602667: Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Active, not recruiting
2
293
US, RoW
Induction Chemotherapy, MTX (methotrexate), Oncovin(R) (vincristine), Platinol-AQ(R) (cisplatin), Cytoxan(R) (cyclophosphamide), Low-Risk Therapy, Paraplatin(R) (carboplatin), Vepesid(R), VP-16 (etoposide), Hycamptin(R) (topotecan), Tarceva(TM) (erlotinib), High-Risk Therapy, Velban(R) (vinblastine), Intermediate-Risk Therapy
St. Jude Children's Research Hospital, University of Florida, National Cancer Institute (NCI), The Pew Charitable Trusts
Brain and Central Nervous System Tumors
09/17
04/26
2019-005039-94: Ocular conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome Traitements conservateurs du rétinoblastome: efficacité des nouvelles stratégies et devenir visuel

Not yet recruiting
2
225
Europe
Lyophilisate for solution for infusion, Solution for solution for infusion, Solution for infusion, Solution for solution for injection, Solution for injection, ALKERAN Injectable, TOPOTECANE ACCORD 1mg/ml, TOPOTECAN HOSPIRA, CARBOPLATINE HOSPIRA, ETOPOSIDE MYLAN 20 mg/ml, VINCRISTINE HOSPIRA 2 mg/2 ml
Institut Curie, PHRC-K 2018 Public Health Grant
Retinoblastoma Rétinoblastome, Eye cancer Cancer de l'oeil, Diseases [C] - Eye Diseases [C11]
 
 
2019-000742-35: PROTOCOL FOR THE DIAGNOSIS AND THERAPY OF INTRAOCULAR RETINOBLASTOMA PROTOCOLLO DIAGNOSTICO E TERAPEUTICO DEL RETINOBLASTOMA INTRAOCULARE

Not yet recruiting
2
44
Europe
Carboplatino, Topotecan, Vincristina Solfato, Etoposide, Melfalan Cloridrato, [Carbo], [Topotecan], [Vcr], [VP16], [Melphalan], Concentrate for solution for infusion, Solution for injection, Powder and solvent for solution for injection
ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
Intraocular retinoblastoma Retinoblastoma intraoculare, Intraocular retinoblastoma Retinoblastoma intraoculare, Diseases [C] - Cancer [C04]
 
 
NCT02822157 / 2015-005838-22: Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer

Active, not recruiting
2
160
Europe
Olaparib, Lynparza, carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
Universitaire Ziekenhuizen Leuven, AstraZeneca
Ovarian Epithelial Cancer
07/21
07/23
BEACON, NCT02308527 / 2012-000072-42: Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children

Active, not recruiting
2
225
Europe
Bevacizumab, Avastin, Temozolomide, Temodal, Irinotecan, Campto, Topotecan, Dinutuximab Beta, Qarziba, Cyclophosphamide
University of Birmingham, Cancer Research UK, Roche Pharma AG, Imagine for Margo, EUSA Pharma, Inc.
Neuroblastoma
08/21
02/26
NCT01857934: Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruiting
2
153
US
cyclophosphamide, Cytoxan(R), topotecan, Hycamtin(R), hu14.18K322A, humanized anti-GD2 antibody, monoclonal antibody, dinutuximab, peripheral blood stem cell harvest, PBSCH, surgical resection, cisplatin, Platinol-AQ(R), etoposide, VP16, Vepesid(R), Etopophos(R), doxorubicin, Adriamycin(R), vincristine, Oncovin(R), busulfan, Busulfex(R), melphalan, L-phenylalanine mustard, Phenylalanine mustard, L-PAM, L-sarcolysin, Alkeran(R), peripheral blood stem cell transplantation, PBSCT, natural killer cell infusion, NK cell infusion, radiation therapy, GM-CSF, sargramostim, Leukine(R), granulocyte macrophage colony stimulating factor, G-CSF, Granulocyte colony stimulating factor, Neupogen(R), Filgrastim, mesna, Mesnex(R), levetiracetam, Keppra, interleukin-2, IL-2, aldesleukin, Proleukin(R), Isotretinoin, 13-cis retinoic acid, CliniMACS, Cell Selection System
St. Jude Children's Research Hospital, Cookies for Kids' Cancer, CURE Childhood Cancer, Inc.
Neuroblastoma
10/21
12/24
NCI-2018-03732, NCT03786783: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Active, not recruiting
2
42
US, RoW
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Dexrazoxane, 2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI), 2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI), ADR-529, ICRF-187, Razoxane (+)-form, Soluble ICRF (L-isomer), Dinutuximab, Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, monoclonal antibody Ch14.18, Qarziba, Unituxin, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Isotretinoin, 13-cis retinoic acid, 13-cis-Retinoate, 13-cis-Retinoic Acid, 13-cis-Vitamin A Acid, 13-cRA, Absorica, Accure, Accutane, Amnesteem, cis-Retinoic Acid, Cistane, Claravis, Isotretinoinum, Isotrex, Isotrexin, Myorisan, Neovitamin A, Neovitamin A Acid, Oratane, Retinoicacid-13-cis, Ro 4-3780, Ro-4-3780, Roaccutan, Roaccutane, Roacutan, Sotret, ZENATANE, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Topotecan, Hycamptamine, Topotecan Lactone, Vincristine, LCR, Leurocristine, VCR, Vincrystine
National Cancer Institute (NCI)
Ganglioneuroblastoma, High Risk Neuroblastoma
12/21
09/24
NCT04162041: Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer

Recruiting
2
12
US
Topotecan + M6620, Topotecan
National Cancer Institute (NCI)
Carcinoma, Small Cell, Solid Tumors, SCLC, Extrapulmonary Lung Cancer, Relapse
06/22
12/22
2021-004807-42: A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Estudio en fase II de MORAb-202 en el cáncer seroso de alto grado resistente al platino, de ovario peritoneal primario o de trompas de Falopio

Not yet recruiting
2
150
Europe
MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin, BMS-986445, L01C D01, L01DB01, Lyophilisate for solution for infusion, Concentrate for solution for infusion, Paclitaxel, Pegylated Liposomal Doxorubicin, topotecan
Bristol-Myers Squibb International Corporation, BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION, Bristol -Myers Squibb International Corporation Belgium, Bristol-Myers Squibb International Corporation Belgium
Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Cáncer seroso de alto grado resistente al platino, de ovario peritoneal primario o de trompas de Falopio, Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Cáncer de ovario, peritoneal primario o de trompas de Falopio, Diseases [C] - Cancer [C04]
 
 
NCT01783535: Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma

Active, not recruiting
2
174
US
vincristine, VCR, Oncovin(R), topotecan, TOPO, Hycamtin(R), filgrastim, G-CSF, Neupogen(R), PEG-filgrastim, pegylated filgrastim, PEG filgrastim, SD-01, Neulasta(R), carboplatin, CARBO, Paraplatin(R), focal therapy, cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy, thermo-chemotherapy, episcleral plaque brachytherapy, etoposide, ETOP, VP-16, Vepesid(R), Etopophos(R), cyclophosphamide, CYCLO, Cytoxan(R), MESNA, Mesnex(R), doxorubicin, DOXO, Adriamycin(R), enucleation, eye removal, external beam radiation or proton beam radiation, EBRT
St. Jude Children's Research Hospital
Retinoblastoma
03/23
01/28
NRG-GY029, NCT05295589: Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Withdrawn
2
96
US
Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Topotecan Hydrochloride, Hycamptamine, Hycamtin, SKF S-104864-A, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI), NRG Oncology
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
03/23
03/23
NCT02312245: Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed
2
13
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemzar, LY-188011, LY188011, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, DOX-SL, Doxil, Doxilen, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Topotecan Hydrochloride, Hycamptamine, Hycamtin, SKF S-104864-A, Topotecan HCl, topotecan hydrochloride (oral)
Mayo Clinic, National Cancer Institute (NCI)
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
04/23
04/23
EuRbG2018, NCT04455139: A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma

Terminated
2
2
Europe
Topotecan, hycamtin, Melphalan, alkeran
Prof. Beck Popovic Maja
Eye Cancer, Retinoblastoma
05/23
05/23
NCT03289910: Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Active, not recruiting
2
25
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Topotecan, Hycamptamine, Topotecan Lactone, Topotecan Hydrochloride, Evotopin, Hycamtin, Potactasol, SKF S-104864-A, Topotec, Topotecan HCl, topotecan hydrochloride (oral), Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Polycythemia Vera, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
05/23
12/24
DDRiver SCLC 250, NCT04768296 / 2020-004231-25: Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer

Completed
2
76
Europe, Japan, US, RoW
Berzosertib, M6620, Topotecan
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Small-cell Lung Cancer
07/23
07/23
NCT03896503: Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Active, not recruiting
2
81
US
Berzosertib, 2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-, M 6620, M6620, VX 970, VX-970, VX970, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Potactasol, SKF S-104864-A, Topotec, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI)
Bladder Small Cell Neuroendocrine Carcinoma, Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Recurrent Lung Small Cell Carcinoma
12/22
01/25
NRG-GY023, NCT04739800: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Active, not recruiting
2
120
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Computed Tomography with Contrast, Contrast Enhanced Computed Tomography, CONTRAST ENHANCED CT SCAN, Contrast-enhanced Computed Tomography, CT Scan With Contrast, CT with Contrast, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Potactasol, SKF S-104864-A, Topotec, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI), NRG Oncology
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Mucinous Adenocarcinoma, Recurrent Fallopian Tube Transitional Cell Carcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Seromucinous Carcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Transitional Cell Carcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma, Refractory Fallopian Tube Clear Cell Adenocarcinoma, Refractory Fallopian Tube Endometrioid Adenocarcinoma, Refractory Fallopian Tube High Grade Serous Adenocarcinoma, Refractory Fallopian Tube Mucinous Adenocarcinoma, Refractory Fallopian Tube Transitional Cell Carcinoma, Refractory Fallopian Tube Undifferentiated Carcinoma, Refractory Low Grade Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian Endometrioid Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Refractory Ovarian Low Grade Serous Adenocarcinoma, Refractory Ovarian Mucinous Adenocarcinoma, Refractory Ovarian Seromucinous Carcinoma, Refractory Ovarian Transitional Cell Carcinoma, Refractory Ovarian Undifferentiated Carcinoma, Refractory Primary Peritoneal Clear Cell Adenocarcinoma, Refractory Primary Peritoneal Endometrioid Adenocarcinoma, Refractory Primary Peritoneal High Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Transitional Cell Carcinoma, Refractory Primary Peritoneal Undifferentiated Carcinoma
01/23
01/25
CA116-001, NCT05613088: A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recruiting
2
90
Europe, Japan, US, RoW
MORAb-202, BMS-986445, Farletuzumab Ecteribulin, Paclitaxel, Bendalis, Pegylated Liposomal Doxorubicin (PLD), Caelyx, Topotecan, Hycamtin
Bristol-Myers Squibb, Eisai Inc.
Neoplasms, Ovarian
06/24
10/26
NCT04607954: Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Recruiting
2
106
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Lurbinectedin, PM01183, Zepzelca
Mayo Clinic, National Cancer Institute (NCI)
Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma, Refractory Extensive Stage Lung Small Cell Carcinoma
11/24
11/25
TOPO-RD, NCT05523869: Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment With Proliferative Vitreoretinopathy

Recruiting
2
50
Canada
Intravitreal topotecan, Pars plana vitrectomy with or without scleral buckle
Unity Health Toronto
Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
02/25
02/25
SJATRT, NCT02114229: Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

Active, not recruiting
2
125
US
alisertib, methotrexate, MTX, cisplatin, Platinol-AQ, carboplatin, paraplatin, cyclophosphamide, cytoxan, etoposide, VP-16, Vepesid, Etoposide phosphate (Etopophos), topotecan, Hycamtin, vincristine, Oncovin, Surgical resection, surgical management, Radiation therapy, Craniospinal irradiation (CSI), Radiotherapy
St. Jude Children's Research Hospital, Millennium Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc.
Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
09/25
09/27
NCT05736952: Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer

Withdrawn
2
32
RoW
Oral Topotecan Combined With Anlotinib
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Platinum-resistant Ovarian Cancer
02/26
02/26
NCT02364713: MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Active, not recruiting
2
66
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, MV-NIS, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Quality-of-Life Assessment, Quality of Life Assessment, Topotecan Hydrochloride, Hycamptamine, Hycamtin, SKF S-104864-A, Topotecan HCl, topotecan hydrochloride (oral)
Mayo Clinic, National Cancer Institute (NCI)
Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
03/27
02/28
NCT04322318: A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Recruiting
2
221
Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Irinotecan, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery, Topotecan, Hycamptamine, Topotecan Lactone, Transabdominal Ultrasound, abdominal ultrasound, TUS, Vincristine, LCR, Leurocristine, VCR, Vincrystine, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
Children's Oncology Group, National Cancer Institute (NCI)
Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
07/27
07/27
NCT05303727: Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Not yet recruiting
2
64
RoW
Anti Thymocyte Globulin, ATG, Fludarabine, Fludara, Cyclophosphamide injection, CTX, Topotecan, Topotecan Hydrochloride, Melphalan, Alkeran, Thiotepa, thiophosphoramide, Busulfan, Busulfex, Cyclosporine, Sandimmune, Tacrolimus, Prograf, Mycophenolate Mofetil, Cellcept, Methotrexate, amethopterin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Neuroblastoma
08/27
08/27
NCT05800587: Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Recruiting
2
280
US
Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel, Docetaxel, Gemcitabine, Etoposide, Irinotecan, Topotecan, Lurbinectedin
Fox Chase Cancer Center
Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer
08/28
08/29
NCT05535166: Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Recruiting
2
120
US
Surgical resection, surgical management, Ommaya/VPS, Methotrexate, MTX, amethopterin, Rexall®, Cisplatin, CDDP, cis-DDP, Platinol-AQ®, Vincristine, Oncovin®, Cyclophosphamide, Cytoxan®, Carboplatin, Paraplatin®, Topotecan, Hycamtin®, Etoposide, VP-16, Vepesid®, Pegfilgrastim, Udenyca®, Filgrastim, GCSF, Neupogen®, Irradiation, Radiotherapy, Educational and Media Intervention, SOC, Educational and Media Intervention
St. Jude Children's Research Hospital
Medulloblastoma
07/35
07/35
NCT00452959: Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors

Active, not recruiting
1/2
18
US
Topotecan
Jeffrey N. Bruce, National Cancer Institute (NCI), Herbert Irving Comprehensive Cancer Center
Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligodendroglioma, Recurrent Anaplastic Oligo-Astrocytoma, Recurrent Glioblastoma Multiforme
02/13
03/13
NCT01012817: Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Active, not recruiting
1/2
88
US
Laboratory Biomarker Analysis, Pharmacogenomic Study, PHARMACOGENOMIC, Pharmacological Study, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Potactasol, SKF S-104864-A, Topotec, Topotecan HCl, topotecan hydrochloride (oral), Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable Solid Neoplasm
01/19
08/24
NCT02487095: Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

Active, not recruiting
1/2
62
US
Topotecan, Hycamtin, VX-970 (M6620), M6620
National Cancer Institute (NCI)
Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma, Uterine Cervical Neoplasms, Carcinoma, Neuroendocrine, Extrapulmonary Small Cell Cancer
02/21
10/25
NCT03227016: Study in Patients With SCLC of Veliparib in Combination With Topotecan

Recruiting
1/2
30
Europe
veliparib, PARP inhibitor, Topotecan, Hycamtin
Central European Society for Anticancer Drug Research
Small Cell Lung Cancer SCLC
05/21
06/21
2021-005617-14: Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II) Estudio para evaluar la seguridad e identificar la dosis de ribociclib en combinación con temozolomida y topotecán (TOTEM) en pacientes (12 meses - 21 años) con tumores sólidos recidivantes o refractarios (Fase I) y evaluar la eficacia y seguridad en pacientes (12 meses - 21 años) con neuroblastoma recidivante o refractario (Fase II)

Ongoing
1/2
230
Europe, RoW
ribociclib, temozolomida 5 mg cápsulas duras, topotecan, temozolomida 20 mg cápsulas duras, temozolomida 100 mg cápsulas duras, temozolomida 140 mg cápsulas duras, temozolomida 180 mg cápsulas duras, temozolomida 250 mg cápsulas duras, LEE011, Powder for oral solution, Capsule, hard, Concentrate for solution for infusion, Temozolomid SUN & Temozolomid Accord, Potactasol & Hycamtin
Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG
relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years old neuroblastoma recidivante o refractario y otros tumores sólidos (incluyendo meduloblastoma, glioma de alto grado, tumores rabdoides malignos y rabdomiosarcoma) en pacientes con edades comprendidas entre los 12 meses y los 21 años, Recurrent solid tumors in patients from 12 months to 21 years old Tumores sólidos recurrentes en pacientes con edades comprendidas entre los 12 meses y los 21 años, Diseases [C] - Cancer [C04]
 
 
NCT03554473: M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Recruiting
1/2
80
US
M7824, Topotecan, Temozolomide
National Cancer Institute (NCI)
Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
01/25
01/25
NCT03709680 / 2021-003444-25: Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Active, not recruiting
1/2
128
Europe, Canada, US, RoW
Palbociclib, Ibrance, Temozolomide, Temodar, Irinotecan, Campto, Topotecan, Hycamtin, Cyclophosphamide, Cytoxan
Pfizer, Children's Oncology Group (COG)
Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma
08/24
02/25
NCT05266196: A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Enrolling by invitation
1/2
10
US
Seclidemstat, topotecan, cyclophosphamide
Salarius Pharmaceuticals, LLC
Ewing Sarcoma, Myxoid Liposarcoma, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Myoepithelial Tumor, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma
12/25
12/25
NCT04029688 / 2018-004579-11: A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Active, not recruiting
1/2
38
Europe, Canada, US
Idasanutlin, RG7388, Venetoclax, RG7601, GDC-0199, ABT-199, Cyclophosphamide, Topotecan, Fludarabine, Cytarabine, Intrathecal Chemotherapy
Hoffmann-La Roche
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
06/24
12/25
ESMART, NCT02813135 / 2016-000133-40: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Recruiting
1/2
460
Europe
Ribociclib, Kisqali, LEE011, Topotecan, Hycamtin, Temozolomide, Temodar, Everolimus, Afinitor, Adavosertib, AZD1775, Carboplatin, Paraplatin, Olaparib, Lynparza, Irinotecan, Camptosar, CPT-11, Vistusertib, AZD2014, Nivolumab, Opdivo, Cyclophosphamide, Cytoxan, Selumetinib, Koselugo, Enasidenib, Idhifa, Lirilumab, BMS-986015, Fadraciclib, CYC065, Cytarabine, Arabinosylcytosine, Cytosar-U, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Maxidex, Ceralasertib, AZD6738, Futibatinib, Tas-120, Capmatinib, Tabrecta, INC280
Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France
Pediatric Cancer
08/27
08/27
NCT05429502 / 2021-005617-14: Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Recruiting
1/2
231
Europe, US, RoW
Topotecan, Hycamtin, Temozolomide, Temodar, Ribociclib, Kisqali, LEE011
Novartis Pharmaceuticals, Innovative Therapies For Children with Cancer Consortium
Neuroblastoma
10/28
01/29

Download Options